Severe COVID-19 Infection, Death Risk Higher in Comorbid Interstitial Lung Disease
Patients with interstitial lung disease have an increased risk of severe disease and death associated with COVID-19.
Patients with interstitial lung disease have an increased risk of severe disease and death associated with COVID-19.
Current guidelines from Italy, the UK, and China do not focus on screening patients for anosmia as a potential symptom for COVID-19.
The Advisory Committee on Immunization Practices encourages all Americans to receive the flu vaccine between September and October.
Dr. Razzaghi and colleagues estimated the county-level prevalence of selected conditions associated with severe COVID-19.
The CDC presented recommendations for testing and clinical management of health care personnel exposed to the hepatitis C virus.
A team of investigators assessed clinical outcomes among patients with COVID-19 receiving ibuprofen for fever reduction.
Researchers explored the question of the seasonality of SARS-CoV-2 by reviewing evidence related to viral viability, transmission, ecological patterns, and observed epidemiology of COVID-19 in the Southern Hemispheres’ summer and early fall.
Dr Harvey W. Kaufman and colleagues examined the results of LBC/HPV cotesting in 13,633,071 women aged ≥30 years, tested in 2010 to 2018.
The American College of Rheumatology developed recommendations for decision-making to distinguish between the need for in-person urgent and virtual nonurgent medical care.
A registry has been created for reporting skin manifestations of COVID-19 following reports of patients presenting with skin conditions.